Two Sigma Securities’s Axsome Therapeutics AXSM Stock Holding History

Two Sigma Securities’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,650	Closed	-$1.4M	–	1657
2025 Q4	$1.4M	Buy	+7,650	New	+$1.07M	0.19%	122
2025 Q3	–	Sell	-2,228	Closed	-$233K	–	1395
2025 Q2	$233K	Buy	+2,228	New	+$236K	0.03%	828
2024 Q2	–	Sell	-2,938	Closed	-$234K	–	2971
2024 Q1	$234K	Buy	+2,938	New	+$247K	﹤0.01%	2193
2020 Q1	–	Sell	-2,957	Closed	-$306K	–	1375
2019 Q4	$306K	Buy	+2,957	New	+$119K	﹤0.01%	1777
2018 Q2	–	Sell	-20,126	Closed	-$49K	–	2633
2018 Q1	$49K	Buy	+20,126	New	+$60.3K	﹤0.01%	2504

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Securities's AXSM Position: Q1 2026 in Review

Two Sigma Securities sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 7,650 shares — an estimated $1.4M sold.

Two Sigma Securities first reported a position in AXSM in Q1 2018 and held it in 5 quarters. The position peaked at $1.4M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Two Sigma Securities reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
Two Sigma Securities sold 7,650 Axsome Therapeutics shares in Q1 2026, an estimated $1.4M.
Two Sigma Securities first reported a position in Axsome Therapeutics in Q1 2018 and held it in 5 quarters.
Two Sigma Securities's Axsome Therapeutics position peaked at $1.4M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.